Centre Georges François Leclerc

Running trials

• Not yet recruiting

  Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer

  NCT07587827· Phase 1· Source

• Recruiting

  Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis

  NCT07376512· Source

• Recruiting

  A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

  NCT07768189· Phase 3· Source

• Recruiting

  A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

  NCT07701941· Phase 1/2· Source

• Not yet recruiting

  SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer

  NCT07241273· Source

• Not yet recruiting

  Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy

  NCT07357948· Source

• Not yet recruiting

  Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer

  NCT07637851· Phase 1/2· Source

• Recruiting

  A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

  NCT07492680· Phase 2· Source

• Recruiting

  Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.

  NCT05937906· Phase 1/2· Source

• Recruiting

  A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

  NCT07359820· Phase 2· Source

• Recruiting

  Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma

  NCT07234058· Phase 2· Source

• Not yet recruiting

  A Study Evaluating the Contribution of Non-Coplanar Beam Arrangement in Reducing Toxicity in Radiotherapy for Upper Aerodigestive Tract Cancers

  NCT07413627· Source

• Recruiting

  Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance

  NCT07483983· Phase 2· Source

• Recruiting

  Phase 2, Multicenter, Open label, Platform Study investigating ASP3082 in patients with Metastatic/Locally Advanced Non-Small-Cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), with biomarker analysis to characterize response/resistance (UNLOCK ASP3082)

  2025-522533-54-00· Phase 2· Source

• Recruiting

  Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11)

  NCT07043543· Source

• Recruiting

  Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer

  NCT06755359· Source

• Recruiting

  Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

  NCT06937905· Phase 3· Source

• Recruiting

  Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

  NCT07227298· Phase 1/2· Source

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Source

• Recruiting

  Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer

  NCT07001618· Phase 2· Source

• Recruiting

  Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.

  NCT07195344· Phase 4· Source

• Not yet recruiting

  Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers

  NCT07097064· Phase 2· Source

• Recruiting

  A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

  NCT07169734· Phase 1/2· Source

• Recruiting

  DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

  NCT06953089· Phase 2· Source

• Recruiting

  Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib

  NCT06620835· Phase 2· Source

• Recruiting

  BreAK CRC (001) trial

  2024-512011-45-00· Phase 1/2· Source

• Not yet recruiting

  Evaluation of the Effect of Adapted Physical Activity on the Modification of Lipid Metabolism During Chemotherapy for Metastatic COLorectal Cancer

  NCT06944548· Phase 2· Source

• Recruiting

  Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma

  NCT06934057· Phase 4· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

  NCT06644781· Phase 3· Source

• Recruiting

  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  NCT06731478· Phase 3· Source

• Not yet recruiting

  Systemic Antitumor Treatment with or Without Pressurized Intraperitoneal Aerosol Chemotherapy for Colon Peritoneal Metastases (PIPOX02)

  NCT06681038· Phase 2· Source

• Recruiting

  A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors

  NCT06747585· Phase 1/2· Source

• Recruiting

  Prognostic Value of Measuring CtDNA in a Cohort of Patients With Stage III and IV Upper Aero-digestive Tract (UADT) Cancer , Treated With Curative RADiOtherapy With or Without Concomitant Treatment.

  NCT06479070· Source

• Recruiting

  Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian Cancer

  NCT06572735· Source

• Recruiting

  Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

  NCT06476184· Phase 3· Source

• Recruiting

  Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

  NCT06333314· Phase 2· Source

• Active, not recruiting

  A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

  NCT06360354· Phase 1· Source

• Active, not recruiting

  S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP

  NCT06188702· Phase 1/2· Source

• Recruiting

  First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer

  NCT06253611· Phase 2· Source

• Recruiting

  CARE1 Pragmatic Clinical Trial

  NCT06364631· Phase 3· Source

• Recruiting

  A Phase 1/1b Study of IAM1363 in HER2 Cancers

  NCT06253871· Phase 1· Source

• Recruiting

  Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy

  NCT05988814· Phase 2· Source

• Recruiting

  PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer

  NCT05581121· Phase 3· Source

• Recruiting

  DESTINY Breast Respond HER2-(Ultra)Low Europe

  NCT05945732· Source

• Recruiting

  Impact of Non-magnetic Screen Respiratory Self-guidance During MRI-guided Radiotherapy Sessions for Mobile Lesions

  NCT05783908· Source

• Recruiting

  Study Comparing Negative Pressure Dressing vs Conventional in Patients With Resected STS After Radiotherapy

  NCT05944913· Source

• Active, not recruiting

  Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer

  NCT05462613· Phase 2/3· Source

• Recruiting

  Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

  NCT05786924· Phase 1/2· Source

• Active, not recruiting

  Reduction of hormone therapy duration in women with hormonesensitive breast cancer at very low risk of metastatic recurrence

  NCT05297617· Phase 2· Source

• Recruiting

  Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

  NCT05528952· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer17 recruiting
• Colorectal cancer9 recruiting
• Pancreatic cancer9 recruiting
• Head and neck cancer8 recruiting
• Ovarian cancer7 recruiting
• Gastric and esophageal cancer5 recruiting
• Liver and biliary tract cancer5 recruiting
• Sarcoma5 recruiting
• Childhood cancers4 recruiting
• Kidney cancer4 recruiting
• Metastatic breast cancer4 recruiting
• Bladder cancer3 recruiting
• Melanoma3 recruiting
• Cervical cancer2 recruiting
• Neuroendocrine tumours2 recruiting
• Endometrial cancer1 recruiting
• Mesothelioma1 recruiting
• Neuroblastoma1 recruiting
• Prostate cancer1 recruiting
• Thyroid cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study

  NCT06599463· Source

• Terminated

  Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment

  NCT06505018· Source

• Withdrawn

  Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures

  NCT06084689· Phase 2· Source

• Completed

  Impact on Quality of Life and Health of the CONTINUUM+ CONNECT Remote Monitoring Solution

  NCT06379880· Source

• Withdrawn

  Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

  NCT05743270· Phase 2· Source

• Completed

  Study of DF6215 in Patients With Advanced Solid Tumors

  NCT06108479· Phase 1· Source

• Completed

  A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients

  NCT05487248· Source

• Terminated

  A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

  NCT05983367· Phase 2· Source

• Terminated

  A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer

  NCT05678257· Phase 2· Source

• Terminated

  Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial 166Holmium Radiation Therapy in Combination With Atezolizumab and Bevacizumab for Non Resectable Hepatocellular Carcinoma

  NCT05705791· Source

• Completed

  A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).

  NCT05578872· Phase 1/2· Source

• Terminated

  Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer

  NCT05442749· Phase 2· Source

• Completed

  A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults

  NCT05361434· Source

• Recruiting

  TARGETed Therapy Drug MONITOring in DIGestive Oncology

  NCT05443087· Source

• Recruiting

  Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

  NCT05378204· Source

• Completed

  A clinical study to test the safety and efficacy of GB1211 in combination with atezolizumab in patients with Non-Small Cell Lung Cancer (NSCLC).

  NCT05240131· Phase 1/2· Source

• Completed

  MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

  NCT05007106· Phase 2· Source

• Terminated

  Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

  NCT04854499· Phase 2· Source

• Terminated

  Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).

  NCT04949256· Phase 3· Source

• Terminated

  Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

  NCT04698915· Phase 2· Source

• Completed

  Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)

  NCT04739202· Phase 2· Source

• Terminated

  Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

  NCT04093362· Phase 3· Source

• Completed

  Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

  NCT04662710· Phase 3· Source

• Completed

  Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer

  NCT04534218· Phase 2· Source

• Completed

  Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

  NCT04641871· Phase 1· Source

• Completed

  In Situ Immune Parameters and Their Prognostic Role on the Survival of Patients With Glioblastoma

  NCT03481231· Source

• Completed

  Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer

  NCT04263051· Phase 2· Source

• Completed

  A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer

  NCT04322539· Phase 3· Source

• Terminated

  Futibatinib in Patients With Specific FGFR Aberrations

  NCT04189445· Phase 2· Source

• Completed

  Effect of Irradiation Doses < 10 Gy and of Irradiated Bone Volume on the Variation of Blood Elements of the Complete Blood Count During and After Pelvic Irradiation

  NCT04626466· Source

• Completed

  MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)

  NCT04495621· Phase 1/2· Source

• Completed

  First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma

  NCT04116658· Phase 1/2· Source

• Completed

  Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma

  NCT04280848· Phase 2· Source

• Completed

  Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

  NCT04210115· Phase 3· Source

• Completed

  Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)

  NCT03946358· Phase 2· Source

• Completed

  A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

  NCT04083976· Phase 2· Source

• Completed

  Molecular Profiling of Advanced Soft-tissue Sarcomas

  NCT03784014· Phase 3· Source

• Terminated

  Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies

  NCT03673332· Phase 4· Source

• Completed

  Trial evaluating the tolerance and safety of durvalumab - radiotherapy combination for treatment of cancers of the head and neck

  2024-513977-31-00· Phase 2· Source

• Completed

  FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel

  NCT03723967· Phase 2· Source

• Completed

  Phase II Study of Regorafenib as Maintenance Therapy

  NCT03793361· Phase 2· Source

• Completed

  Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer

  NCT03828799· Phase 1/2· Source

• Completed

  Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

  NCT03778931· Phase 3· Source

• Completed

  Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer

  NCT03941093· Phase 3· Source

• Completed

  A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

  NCT03782207· Source

• Completed

  UTOLA: UTerin OLAparib

  NCT03745950· Phase 2· Source

• Completed

  Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

  NCT03777657· Phase 3· Source

• Completed

  Study of Exosomes in Monitoring Patients With Sarcoma (EXOSARC)

  NCT03800121· Source

• Completed

  MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

  NCT03767335· Phase 1· Source

• Completed

  Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer

  NCT03579394· Source

Trial sites

• Center Georges-Francois Leclerc0 trials
• Centre de Lutte Contre le Cancer, Georges-Francois Leclerc1 trial
• Centre Georges François Leclerc148 trials
• Centre Georges-François Leclerc, Department of Medical Oncology1 trial
• Centre Georges Francois Leclerc, Department of Oncology1 trial
• Centre Georges François Leclerc Dijon2 trials
• Centre Georges François Leclerc /ID# 2267601 trial
• Centre Georges François Leclerc /ID# 2444500 trials
• Centre Georges Francois Leclerc /ID# 2767370 trials
• Centre Georges Francois Leclerc - Oncologie Medicale2 trials
• Centre Georges-François Leclerc - Service d'Oncologie0 trials
• Centre Georges Francois Leclerc - service d'oncologie médicale0 trials
• Centre Georges Francois Leclerc (Site 0223)1 trial
• Centre Georges Francois Leclerc (Site 0488)0 trials
• Centre Georges François Leclerc (Site 0506)0 trials
• Centre Georges François Leclerc (Site 0805)0 trials
• Centre Georges Francois Leclerc (Site 1008)1 trial
• Centre Georges Francois Leclerc (Site 1106)1 trial
• Centre Georges François Leclerc (Site 1155)1 trial
• Centre Georges François Leclerc (Site 1210)0 trials
• Centre Georges François Leclerc (Site 1312)0 trials
• Centre Georges Francois Leclerc (Site 3902)0 trials
• CTR Georges-François Leclerc1 trial
• Dijon - Centre Georges-François Leclerc3 trials
• Service de Chirurgie Digestive, Centre Georges François Leclerc - Dijon1 trial
• Centre Georges Francois Leclerc1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Metastatic breast cancer17 works · 15 trials